G-Protein Coupled Receptor (GPCR) Targeting Market Revolutionizes Cell Signaling Research | United States & Asia-Pacific

DataM Intelligence has released its latest "G-Protein Coupled Receptor (GPCR) Targeting Market Size 2026" report, delivering comprehensive insights into market trends, growth opportunities, competitive dynamics, and regional performance. The report covers market size by value and volume, CAGR forecasts, and emerging opportunities, the report delivers data-driven insights into industry developments, competitive trends, and future market outlook, enabling more effective strategic planning and market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/g-protein-coupled-receptor-targeting-market?kb

United States: Recent Industry Developments

✅ June 2026: XtalPi entered a strategic partnership with a leading global biopharmaceutical company to develop AI-driven oral small-molecule therapeutics targeting a G-Protein Coupled Receptor (GPCR), with the collaboration valued at over US$400 million in potential milestones.

✅ June 2026: Combotope Therapeutics and Boehringer Ingelheim announced a strategic research collaboration to discover next-generation tumor-selective antibody therapies targeting cancer-specific glycan-protein complexes, expanding precision oncology research.

✅ April 2026: Nxera Pharma achieved a second development milestone in its multi-target GPCR collaboration with Eli Lilly for metabolic disease therapies, validating its GPCR-focused drug discovery platform.

✅ January 2026: Researchers introduced GPCR-Filter, an AI-powered deep learning framework designed to accelerate GPCR modulator discovery and improve identification of novel therapeutic candidates.

Find the right strategic partners to accelerate your business. Get started today:- https://www.datamintelligence.com/partner-identification-enquiry/g-protein-coupled-receptor-targeting-market?kb

Top List of Key Player:

Abcam plc, Enzo Life Sciences, Inc, Promega Corporation, PerkinElmer Inc, Thermo Fisher Scientific, Eurofins DiscoverX Products, WuXi AppTec (HD Biosciences Co. Ltd), BioInvenu Inc, Danaher Corporation (Molecular Devices LLC) and Merck KGaA

Latest Investments

• June 2026: Beeline Medicines expanded its Series A financing to US$426.3 million to advance precision therapies for autoimmune and inflammatory diseases, including GPCR-related drug discovery programs.

• June 2026: RQ Bio raised US$115 million in Series A funding to accelerate development of long-acting antibody therapeutics targeting immune pathways associated with GPCR signaling.

• January 2026: CORXEL Pharmaceuticals secured US$287 million in Series D1 financing to advance its oral GLP-1 receptor agonist pipeline for cardiometabolic diseases.

• January 2026: Eli Lilly committed US$100 million as an anchor investor in Aktis Oncology's IPO, strengthening investment in next-generation targeted therapeutics.

Key Industry Developments 2026:

✅ In June 2026, Structure Therapeutics, Inc. announced additional positive clinical data for its oral GLP-1 receptor agonist aleniglipron, demonstrating no signs of drug-induced liver injury while supporting continued advancement into Phase III development for obesity treatment.

✅ In May 2026, Nxera Pharma (formerly Sosei Heptares) achieved a development milestone under its multi-target collaboration with Eli Lilly, focused on GPCR-targeted therapies for diabetes and metabolic diseases. The company also received milestone payments following the initiation of Neurocrine Biosciences' Phase II schizophrenia trial and progress in its neurological disease collaboration with AbbVie.

✅ In April 2026, Neurocrine Biosciences, Inc. initiated a Phase II clinical trial evaluating NBI-1117570, a GPCR-targeted treatment candidate for adults with schizophrenia. The milestone marked further clinical advancement of GPCR-based therapies in central nervous system disorders.

✅ In January 2026, AstraZeneca PLC expanded its cardiometabolic pipeline through a strategic multi-program collaboration with CSPC Pharmaceuticals, gaining access to multiple next-generation therapeutic candidates, including GPCR-related metabolic disease programs and advanced drug delivery technologies.

Growth Forecast Projection 2026:

The Global G-Protein Coupled Receptor (GPCR) Targeting Market is expected to witness significant growth during the forecast period 2026-2033. In 2025, the market is projected to accelerate as leading players continue to implement strategic initiatives that drive adoption. This sustained growth is set to create emerging opportunities and enhance long-term revenue potential across the industry.

How Our Market Research Process Works 2026-2033:

The G-Protein Coupled Receptor (GPCR) Targeting Market report by DataM Intelligence delivers comprehensive insights backed by extensive primary and secondary research. It analyzes key market trends, competitive dynamics, regulatory developments, technological advancements, emerging innovations, and growth opportunities while highlighting potential challenges and evolving market conditions. The report provides actionable intelligence to support strategic planning and identify future market potential.

Latest M & A/ partnerships in 2026:

• January 2026: Eli Lilly announced the acquisition of Ventyx Biosciences to strengthen its pipeline of oral therapies for inflammatory diseases, including GPCR-related small-molecule drug discovery capabilities.

Buy Now & Unlock 360° Complete Market Insights: https://www.datamintelligence.com/buy-now-page?report=g-protein-coupled-receptor-targeting-market?kb

Japan: Recent Industry Developments

✅ June 2026: Nxera Pharma continued advancing its GPCR-focused pipeline through ongoing collaborations with global pharmaceutical partners, strengthening Japan's position in GPCR-based drug discovery for metabolic diseases.

✅ April 2026: Nxera Pharma received a development milestone payment from Eli Lilly after achieving key progress in its GPCR-targeted metabolic disease collaboration, supporting continued innovation in structure-based drug design.

✅ April 2026: Nxera Pharma reported that partner Neurocrine Biosciences initiated a Phase II clinical trial for NBI-1117570, a GPCR-targeted therapy for schizophrenia, triggering a milestone payment under their collaboration.

✅ January 2026: Japanese researchers and biotechnology companies continued expanding the use of AI-enabled GPCR discovery platforms to accelerate identification of novel receptor-targeted therapeutics for neurological and metabolic disorders.

Key Segmentation Plannings (2026):

By Product: Cell Lines, Detection Kits, Cell Culture Reagents, Ligands

By Application Segment: Cancer Research, CNS Research, Metabolic Research, Cardiovascular Research, Respiratory Research, Inflammation Research, Other Application

By End-user: cAMP Functional Assays, Calcium Functional Assays, β-Arrestin Functional Assays, Radioligand Binding and GTPγS Functional Assays, Internalization Assays, Trafficking Assays, Other Assays

Global Market Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Provides a comprehensive introduction to the G-Protein Coupled Receptor (GPCR) Targeting Market, including key segments by region, product type, and application, along with market size, growth potential, and short- and long-term outlook.

Chapter 2 - Emerging Trends: Highlights the latest industry trends, technological advancements, and innovations driving market transformation.

Chapter 3 - Competitive Landscape: Analyzes the competitive environment, including market share, strategic developments, partnerships, and recent mergers and acquisitions.

Chapter 4 - Leading Company Profiles: Presents detailed profiles of major market participants, covering revenue, product portfolios, operating performance, and recent developments.

Chapters 5 & 6 - Regional and Country Analysis: Delivers in-depth insights into market performance across key regions and countries, highlighting revenue trends, growth opportunities, and market potential.

Chapter 7 - Market Segmentation: Examines the market by type, identifying key segments, growth prospects, and high-opportunity areas.

Chapter 8 - Application Analysis: Explores major application areas, emerging demand trends, and sectors contributing to market expansion.

Chapter 9 - Supply Chain Analysis: Maps the end-to-end industry value chain, providing insights into upstream suppliers, downstream channels, and overall market structure.

Chapter 10 - Key Insights and Strategic Outlook: Summarizes the report with actionable insights, strategic recommendations, and growth opportunities to support future market planning.

Request a Customized Market Report Today:- https://www.datamintelligence.com/customize/g-protein-coupled-receptor-targeting-market?kb

G-Protein Coupled Receptor (GPCR) Targeting Market Drivers

Rising Prevalence of Chronic Diseases: Increasing cases of cancer, cardiovascular disorders, neurological diseases, and metabolic conditions are driving demand for GPCR-targeted therapies due to their proven role in disease treatment.

Advancements in Drug Discovery Technologies: AI-driven drug discovery, structure-based drug design, cryo-electron microscopy (cryo-EM), and computational biology are accelerating the identification and development of novel GPCR-targeted drugs.

Growing Biopharmaceutical R&D Investments: Pharmaceutical and biotechnology companies are increasing investments in GPCR research, supported by strategic collaborations, licensing agreements, and expanding clinical pipelines.

Expanding Precision Medicine and Biologics Development: The growing focus on personalized medicine and next-generation biologics is boosting the development of highly selective GPCR-targeted therapies with improved efficacy and reduced side effects.

FAQ's

Q1: How fast is the G-Protein Coupled Receptor (GPCR) Targeting Market expected to grow during the forecast period?

Ans: The market is projected to expand at a CAGR of 6.40% from 2024 to 2031, reflecting strong growth potential over the forecast period.

Q2: Which region leads the G-Protein Coupled Receptor (GPCR) Targeting Market?

Ans: North America accounted for the largest market share in 2025

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.